University of Colorado Hospital
Aurora, Colorado, 80045, United States
NCT Number: NCT05319613
HIV and Sexually Transmitted Infection (STI) rates are increasing in rural areas including rural Colorado. Many rural residents find it difficult to access HIV and STI prevention services.
In this study, an online survey on HIV and STI Prevention and best practices to provide access to prevention will be administered to rural residents in three zip 3 zones in rural Colorado. In addition to the baseline survey, study participants who are interested and medically eligible may initiate PrEP services with the University of Colorado HIV Prevention Program and receive PrEP through telemedicine visits, mailed home lab kits, and mailed medication. Persistence in PrEP care, acceptability, and feasibility of telemedicine and home lab kits will be measured.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Aurora, Colorado, 80045, United States
HIV and Sexually Transmitted Infection (STI) rates are increasing in rural areas including rural Colorado. Many rural residents find it difficult to access HIV and STI prevention services. The goal of this study is to understand the risk for HIV and STIs, views on PrEP, and to determine if access to telemedicine visits and home lab kits increases engagement in PrEP services and persistence in care for at-risk rural populations.
An online survey on HIV and STI Prevention and best practices to provide access to prevention will be administered to rural residents in three zip 3 zones in rural Colorado, comprised of increased proportions of minority residents (Hispanic, Native American, and Black). In addition to the baseline survey, study participants who are interested and medically eligible may initiate PrEP services with the University of Colorado HIV Prevention Program and receive PrEP through telemedicine visits, mailed home lab kits, and mailed medication. Persistence in PrEP care, acceptability, and feasibility of telemedicine and home lab kits will be measured through baseline and follow-up survey questionnaires and clinical chart reviews for those engaged in PrEP care.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
Time frame: 12 months
The proportion of study participants persisting in PrEP care at 12 months, stratified by race, ethnicity, zip 3 region, and type of insurance coverage.
Time frame: 12 months
Describe PrEP medication adherence rates at 12 months (as determined by pharmacy refill data) for rural CO PrEP users who utilize Telemedicine PrEP services and postal lab kits.
Time frame: 12 months
Describe feasibility of Telemedicine visits as determined by survey response and completion of quarterly visits.
Time frame: 12 months
Describe acceptability of Telemedicine visits as determined by survey response and completion of quarterly visits.
Time frame: 12 months
Describe feasibility of postal lab kits, as determined by survey response and completion of quarterly lab monitoring.
Time frame: 12 months
Describe acceptability of postal lab kits, as determined by survey response and completion of quarterly lab monitoring.
Time frame: 12 months
Describe rate of HIV seroconversion in cohort at 12 months.
University of Colorado, Denver
Other
Reducing Disparities in Rural HIV Prevention With Telemedicine PrEP and Postal Lab Kits
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04758390
Blood-Borne Infections, Communicable Diseases
Cape Town, South Africa
View Trial DetailsNCT04677374
Blood-Borne Infections, Communicable Diseases
Lilongwe, Malawi
View Trial DetailsNCT01198418
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial DetailsNCT00849823
Blood-Borne Infections, Communicable Diseases
New Orleans, Louisiana, United States
View Trial Details